Beryl Drugs is currently trading at Rs. 36.50, up by 0.45 points or 1.25% from its previous closing of Rs. 36.05 on the BSE.
The scrip opened at Rs. 36.05 and has touched a high and low of Rs. 38.90 and Rs. 35.65 respectively. So far 60589 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 48.00 on 07-Mar-2014 and a 52 week low of Rs. 18.95 on 21-May-2014.
Last one week high and low of the scrip stood at Rs. 36.60 and Rs. 28.50 respectively. The current market cap of the company is Rs. 18.18 crore.
The promoters holding in the company stood at 24.92 % while Institutions and Non-Institutions held NA % and 75.08 % respectively.
Beryl Drugs has entered into an agreement with the Madhya Pradesh Public Health Services Procurement Corporation (MPPHSCL), Bhopal (M.P.) for supply of the medicines manufactured by the company to the tune of Rs 11.80 crore, which will boost up the company’s turnover by 60% to 65%.
Further, the company has expanded its production capacity from 1.20 crores bottles per year to 2.00 crore bottles per year to fulfill the present and the future requirements of the company.
The company is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1867.80 |
| Dr. Reddys Labs. | 1301.30 |
| Cipla | 1433.10 |
| Zydus Lifesciences | 1112.10 |
| Lupin | 2356.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: